DE69728375T2 - Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen - Google Patents

Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen Download PDF

Info

Publication number
DE69728375T2
DE69728375T2 DE69728375T DE69728375T DE69728375T2 DE 69728375 T2 DE69728375 T2 DE 69728375T2 DE 69728375 T DE69728375 T DE 69728375T DE 69728375 T DE69728375 T DE 69728375T DE 69728375 T2 DE69728375 T2 DE 69728375T2
Authority
DE
Germany
Prior art keywords
optionally substituted
mmol
acid
hydroxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728375T
Other languages
German (de)
English (en)
Other versions
DE69728375D1 (de
Inventor
D. Robert GRONEBERG
W. Kent NEUENSCHWANDER
W. Stevan DJURIC
M. Gerard MCGEEHAN
J. Christopher BURNS
M. Steven CONDON
M. Matthew MORRISSETTE
M. Joseph SALVINO
C. Anthony SCOTESE
W. John ULLRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE69728375D1 publication Critical patent/DE69728375D1/de
Application granted granted Critical
Publication of DE69728375T2 publication Critical patent/DE69728375T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/56—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE69728375T 1996-01-02 1997-01-02 Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen Expired - Lifetime DE69728375T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US948496P 1996-01-02 1996-01-02
US9484P 1996-01-02
PCT/US1997/000264 WO1997024117A1 (en) 1996-01-02 1997-01-02 Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds

Publications (2)

Publication Number Publication Date
DE69728375D1 DE69728375D1 (de) 2004-05-06
DE69728375T2 true DE69728375T2 (de) 2005-02-10

Family

ID=21737943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69728375T Expired - Lifetime DE69728375T2 (de) 1996-01-02 1997-01-02 Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen

Country Status (10)

Country Link
US (1) US6057369A (cg-RX-API-DMAC7.html)
EP (1) EP0871439B1 (cg-RX-API-DMAC7.html)
JP (1) JP4358908B2 (cg-RX-API-DMAC7.html)
AT (1) ATE262899T1 (cg-RX-API-DMAC7.html)
AU (1) AU1529897A (cg-RX-API-DMAC7.html)
DE (1) DE69728375T2 (cg-RX-API-DMAC7.html)
DK (1) DK0871439T3 (cg-RX-API-DMAC7.html)
ES (1) ES2217386T3 (cg-RX-API-DMAC7.html)
PT (1) PT871439E (cg-RX-API-DMAC7.html)
WO (1) WO1997024117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
PT780386E (pt) * 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6118001A (en) * 1996-08-07 2000-09-12 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
EP0929519B1 (en) * 1996-09-27 2005-02-23 PHARMACIA & UPJOHN COMPANY Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6133409A (en) * 1996-12-19 2000-10-17 Aventis Pharmaceuticals Products Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
IL155120A (en) * 1996-12-19 2008-06-05 Aventis Pharma Inc Process for the solid state synthesis of aldehydes, ketones, oximes and hydroxamic acids
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
AU768182B2 (en) * 1996-12-19 2003-12-04 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha,beta-unsaturated carboxylic acid and aldehyde compounds
DE69829648T2 (de) * 1997-01-22 2009-12-10 Aventis Pharmaceuticals Inc. Substituierte β-Thiocarbonsäure
BR9807824A (pt) * 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
ATE256107T1 (de) * 1997-02-27 2003-12-15 Wyeth Corp N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl,sulfinyl oder sulfonyl)-3-substituierte alkyl, aryl oder heteroarylamide als matrix metalloproteinase als matrix metalloproteinase inhibitoren
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
IL131494A (en) 1997-03-04 2005-06-19 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
CN1302206A (zh) * 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
RU2250105C2 (ru) 1997-11-14 2005-04-20 Дж.Д.Сёрл ЛЛС Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз
US6750228B1 (en) * 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
ES2192349T3 (es) 1997-11-21 2003-10-01 Upjohn Co Derivados alfa-hidroxi, amino y halo de acidos hidroxamicos beta-sulfonilo utilizados como inhibidores de metaloproteinas matriciales.
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
DK1357109T3 (da) 1998-06-18 2008-09-08 Hoffmann La Roche Fremgangsmåde til arylalkylsulfid
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6172064B1 (en) * 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
WO2000044723A1 (en) * 1999-01-27 2000-08-03 American Cyanamid Company Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
US6448250B1 (en) 1999-02-08 2002-09-10 G. D. Searle & Company Sulfamato hydroxamic acid metalloprotease inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
GB9929979D0 (en) * 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
AU5652001A (en) 2000-05-15 2001-11-26 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6506773B2 (en) 2000-05-15 2003-01-14 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
FR2809623B1 (fr) * 2000-06-05 2003-09-05 Sanjuan Benito Arranz Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
US8030343B2 (en) 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6689794B2 (en) 2001-05-11 2004-02-10 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200406197A (en) * 2002-04-25 2004-05-01 Ono Pharmaceutical Co Therapelitic agent for inflammatory bowel disease containing hydroxamic acid as effective component
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2003099272A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
WO2004000811A1 (en) * 2002-06-25 2003-12-31 Pharmacia Corporation Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
DK1610678T3 (da) 2003-04-04 2011-10-24 Yeda Res & Dev Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
EP1817020A4 (en) * 2004-11-08 2012-11-21 Errant Gene Therapeutics Inc INHIBITORS OF HISTONATE ACETYLASE
ZA200806778B (en) 2006-02-07 2009-11-25 Astellas Pharma Inc N-Hydroxyacrylamide compounds
WO2009008905A1 (en) * 2007-02-01 2009-01-15 Panthera Biopharma, Llc. Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
US7807720B2 (en) 2007-02-01 2010-10-05 Panthera Biopharma, Llc Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
KR20090113908A (ko) 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
WO2016128131A1 (en) * 2015-02-09 2016-08-18 National And Kapodistrian University Of Athens Beta-lactone inhibitors of phospholipase a2 and uses thereof
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
TW290541B (cg-RX-API-DMAC7.html) * 1993-03-18 1996-11-11 Otsuka Pharma Factory Inc
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
JPH07196598A (ja) * 1993-12-28 1995-08-01 Kuraray Co Ltd ヒドロキサム酸誘導体およびそれを有効成分とする医薬組成物
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
PT780386E (pt) * 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz

Also Published As

Publication number Publication date
DE69728375D1 (de) 2004-05-06
ES2217386T3 (es) 2004-11-01
JP4358908B2 (ja) 2009-11-04
WO1997024117A1 (en) 1997-07-10
DK0871439T3 (da) 2004-08-02
ATE262899T1 (de) 2004-04-15
JP2000503012A (ja) 2000-03-14
PT871439E (pt) 2004-08-31
EP0871439A1 (en) 1998-10-21
EP0871439B1 (en) 2004-03-31
EP0871439A4 (en) 1999-07-21
US6057369A (en) 2000-05-02
AU1529897A (en) 1997-07-28

Similar Documents

Publication Publication Date Title
DE69728375T2 (de) Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
DE69522569T2 (de) Metalloproteinase hemmende verbindungen
DE69732571T2 (de) Beta-sulfonyl-hydroxamsäuren als matrix-metalloproteinaseinhibitoren
KR100853049B1 (ko) 산화질소 신타제 억제제 포스페이트염
DE69835688T2 (de) Substituierte anilide
DE60312017T2 (de) Sulfonderivate zur hemmung von gamma-secretase
DE69710204T2 (de) Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
DE69716449T2 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
DE69815307T2 (de) Cyclische thio-substituierte acylaminosäureamid-derivate
DE69412469T2 (de) Hydroxamsaeurederivate als metalloproteinase inhibitoren
JP2001513771A (ja) マトリクス金属プロテイナーゼ阻害薬としてのｎ−ヒドロキシ−２−（アルキル、アリール、またはヘテロアリールスルファニル、スルフィニルまたはスルホニル）−３−置換アルキル、アリールまたはヘテロアリールアミド
EP0344519A1 (de) Substituierte 4-(Chinolin-2-yl-methoxy)phenyl-essigsäure-Derivate
JP2002537376A (ja) 新規スルホンアミドおよびそれらの使用
DE3631824A1 (de) Cycloalkano(1.2-b)indol-sulfonamide
AU2005299797A1 (en) Heterocyclic indanone potentiators of metabotropic glutamate receptors
WO2003097607A1 (de) Tetrahydroisochinolin-derivate
DE60223692T2 (de) Cyclohexyl-sulphone
DE2342118C2 (de) Phenoxypropionsäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
DE2724948A1 (de) Hydantoinderivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
JP2002535384A (ja) Ｔａｃｅ阻害剤としてのアルキニル含有ヒドロキサム酸化合物
DE69414194T2 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
AT395421B (de) Verfahren zur herstellung von neuen cyclopenthylethern
DE4141218A1 (de) Thiadiazincarbonsaeureamidderivate, verfahren zu ihrer herstellung und arzneimittel
EP0897908A1 (de) 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
KR20020038951A (ko) 베타 이치환된 메탈로프로테아제 저해제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition